The introduction of the Azurion Neuro Biplane system by Philips is likely to have a positive impact on the company's stock in the short term. This is due to the potential for increased sales and market share in the healthcare technology sector, as well as the enhancement of Philips' reputation as a leader in innovation. The system's focus on improving patient outcomes and operational efficiency in neurovascular care could drive demand from healthcare providers, further supporting Philips' financial performance.